Pt. 2 with Dr. Abhishek Mangeshikar: The Silent Struggle of Endometriosis A Global Insight into Patient Care

Send us a text with a question or thought on this episode ( We cannot replay from this link)Discover the harrowing yet hopeful journey through the maze of endometriosis and adenomyosis care with our guest expert Dr. Abhishek Mangeshikar. Experience the solidarity of shared struggles as we dissect the arduous path to an accurate diagnosis and the potential pitfalls of repeated surgical endeavors. Dr. Mangeshikars insights highlight the indispensability of multidisciplinary teams and the promise of alternative therapies in the chronic pain battleground. We also confront the daunting specter of disease recurrence and weigh the long-term consequences of hormonal suppression therapies, while pondering their apparent overuse in certain healthcare systems. It's a dialogue that not only empathizes with the fears and frustrations but also emboldens listeners with expert knowledge and strategies for navigating the complex healthcare landscape of these pervasive conditions.Embark on a global odyssey of endometriosis management with us as we compare how cultural and demographic factors shape the diagnosis and treatment across the world. Dr. Mangeshikar and I investigate the significance of early detection and the role it plays in constructing effective treatment plans, including the potential enlightenment an international study might offer. Delving into the heart of healthcare disparities, this episode offers a critical look at the research hurdles faced by private practitioners and the imperative for adaptable treatment blueprints. Listen as we shed light on the French approach to centralized data collection and what it could mean for the progression of endometriosis care. It's an episode brimming with revelations that empower patients and practitioners alike to forge a path toward more comprehensive and personalized healthcare.Support the showWebsite endobattery.com

There are no comments yet.

Please log in to write the first comment.